Molecular profiles of prostate cancer: To treat or not to treat

Annual Review of Medicine

Volumn 67, Issue , 2016, Pages 119-135

  Sternberg, Itay A ^a   Vela, Ian ^b   Scardino, Peter T ^c  

^a MEIR MEDICAL CENTER   (Israel)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Active surveillance; Genomic classifier; Risk stratification

Indexed keywords

ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SCREENING; CELL CYCLE PROGRESSION; COPY NUMBER VARIATION; GENE EXPRESSION PROFILING; GENOME ANALYSIS; HUMAN; MEDICAL DECISION MAKING; MOLECULAR GENETICS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEOMICS; RISK ASSESSMENT; BLOOD; GENETICS; MALE; PATHOLOGY; PATIENT SELECTION; PROCEDURES; PROSTATIC NEOPLASMS;

TUMOR MARKER;

BIOMARKERS, TUMOR; DNA COPY NUMBER VARIATIONS; GENE EXPRESSION PROFILING; HUMANS; MALE; PATIENT SELECTION; PROSTATIC NEOPLASMS; PROTEOMICS; RISK ASSESSMENT;

EID: 84954539243     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-060413-112226     Document Type: Article

References (65)

1. American Cancer Society (2015). Estimated deaths for the four major cancers by sex and age group, 2015. http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044509.pdf
2. Cooperberg MR, Broering JM, Carroll PR. (2010). Time trends and local variation in primary treatment of localized prostate cancer. J. Clin. Oncol. 28: 1117-23
3. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. (2007). Contemporary trends in low risk prostate cancer: risk assessment and treatment. J. Urol. 178: S14-S19
4. Draisma G, Etzioni R, Tsodikov A, et al. (2009). Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J. Natl. Cancer Inst. 101: 374-83
5. Thompson I, Thrasher JB, Aus G, et al. (2007). Guideline for the management of clinically localized prostate cancer: 2007 update. J. Urol. 177: 2106-31
6. Kattan MW, Cuzick J, Fisher G, et al. (2007). Nomogram incorporating PSA level to predict cancerspecific survival for men with clinically localized prostate cancermanaged without curative intent. Cancer 112: 69-74
7. Taylor BS, Schultz N, Hieronymus H, et al. (2010). Integrative genomic profiling of human prostate cancer. Cancer Cell 18: 11-22
8. Hieronymus H, Schultz N, Gopalan A, et al. (2014). Copy number alteration burden predicts prostate cancer relapse. PNAS 111: 11139-44
9. Cuzick J, Swanson GP, Fisher G, et al. (2011). Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 12: 245-55
10. Klein EA, Cooperberg, MR, Magi-Galluzzi C, et al. (2014). A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur. Urol. 66: 550-60
11. Erho N, Crisan A, Vergara IA, et al. (2013). Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS ONE 8: e66855
12. Blume-Jensen P, Berman DM, Rimm DL, et al. (2015). Development and clinical validation of an in situ biopsy based multi-marker assay for risk stratification in prostate cancer. Clin. Cancer Res. 21: 2591-600
13. Tosoian JJ, Trock BJ, Landis P, et al. (2011). Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J. Clin. Oncol. 29: 2185-90
14. Klotz L, Vesprini D, Sethukavalan P, et al. (2015). Long-Term follow-up of a large active surveillance cohort of patients with prostate cancer. J. Clin. Oncol. 33: 272-77
15. Hricak H, Choyke PL, Eberhardt SC, et al. (2007). Imaging prostate cancer: a multidisciplinary perspective. Radiology 243: 28-53
16. Eifler JB, Feng Z, Lin BM, et al. (2012). An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int. 11: 22-29
17. Stephenson AJ, Scardino PT, Eastham JA, et al. (2006). Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J. Natl. Cancer Inst. 98: 715-17
18. Stephenson AJ, Kattan MW, Eastham JA, et al. (2009). Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J. Clin. Oncol. 27: 4300-5
19. Mohler JL, Kantoff PW, Armstrong AJ, et al. (2014). Prostate cancer, version 2.2014. J. Natl. Cancer Netw. 12: 686-718
20. Cooperberg MR, Pasta DJ, Elkin EP, et al. (2005). The University of California, San Francisco Cancer of the Prostate Risk Assessment Score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J. Urol. 173: 1938-42
21. Mitchell JA, Cooperberg MR, Elkin EP, et al. (2005). Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE. J. Urol. 173: 1126-31
22. Dinh KT, Mahal BA, Ziehr DR, et al. (2015). Incidence and predictors of upgrading and upstaging among 10, 000 contemporary patients with low-risk prostate cancer. J. Urol. 194: 343-49
23. Cuzick J, Fisher G, Kattan MW, et al. (2006). Long-Term outcome amongmen with conservatively treated localised prostate cancer. Br. J. Cancer 95: 1186-94
24. Wilt TJ, Brawer MK, Jones KM, et al. (2012). Radical prostatectomy versus observation for localized prostate cancer. N. Engl. J. Med. 367: 203-13
25. Welty CJ, Cowan JE, Nguyen H, et al. (2015). Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer. J. Urol. 193: 807-11
26. Eggener SE, Mueller A, Berglund RK, et al. (2009). A multi-institutional evaluation of active surveillance for low risk prostate cancer. J. Urol. 181: 1635-41
27. Fütterer JJ, Briganti A, De Visschere P, et al. (2015). Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. Eur. Urol. 68: 1045-53
28. Berglund RK, Masterson TA, Vora KC, et al. (2008). Pathological upgrading and upstaging with immediate repeat biopsy in patients eligible for active surveillance. J. Urol. 180: 1964-67
29. Mullerad M, Hricak H, Wang L, et al. (2004). Prostate cancer: detection of extracapsular extension by genitourinary and general body radiologists at MR imaging. Radiology 232: 140-46
30. Vargas HA, Akin O, Shukla-Dave A, et al. (2012). Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer: a prospective study. Radiology 265: 478-87
31. Brown AM, Elbuluk O, Mertan F, et al (2015). Recent advances in image-guided targeted prostate biopsy
32. Pinto PA, Chung PH, Rastinehad AR, et al. (2011). Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. J. Urol. 186: 1281-85
33. Roychowdhury S, Chinnaiyan M. (2013). Advancing precision medicine for prostate cancer through genomics. J. Clin. Oncol. 31: 1866-73
34. Fraser M, Berlin A, Bristow RG, et al. (2015). Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer. Urol. Oncol. 33: 85-94
35. Knezevic D, Goddard AD, Natraj N, et al. (2013). Analytical validation of the Oncotype DX prostate cancer assay-A clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genomics 14: 690
36. Shipitsin M, Small C, Choudhury S, et al. (2014). Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error. Br. J. Cancer 111: 1201-12
37. Sattler HP, Rohde V, Bonkhoff H, et al. (1999). Comparative genomic hybridization reveals DNA copy number gains to frequently occur in human prostate cancer. Prostate 39: 79-86
38. Yano S, Matsuyama H, Matsuda K, et al. (2004). Accuracy of an array comparative genomic hybridization (CGH) technique in detectingDNA copy number aberrations: comparison with conventional CGH and loss of heterozygosity analysis in prostate cancer. Cancer Genet. Cytogenet. 150: 122-27
39. Liu W, Laitinen S, Khan S, et al. (2009). Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat. Med. 15: 559-65
40. Cheng I, Levin AM, Tai YC, et al. (2012). Copy number alterations in prostate tumors and disease aggressiveness. Genes Chromosomes Cancer 51: 66-76
41. Feik E, Schweifer N, Baierl A, et al. (2013). Integrative analysis of prostate cancer aggressiveness. Prostate 73: 1413-26
42. Cuzick J, Berney DM, Fisher G, et al. (2012). Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br. J. Cancer 106: 1095-99
43. Mosley JD, Keri RA. (2008). Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists. BMC Med. Genomics 1: 11
44. Crawford ED, Shore N, Scardino PT, et al. (2015). Performance of CCP assay in an updated series of biopsy samples obtained from commercial testing. Presented at Genitourinary Cancers Symp. (GU ASCO), Feb. 26-28, Orlando, FL
45. Cooperberg MR, Simko JP, Cowan JE, et al. (2013). Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J. Clin. Oncol. 31: 1428-34
46. Bishoff JT, Freedland SJ, Gerber L, et al. (2014). Prognostic utility of the CCP score generated from biopsy in men treated with prostatectomy. J. Urol. 192: 409-14
47. Freedland SJ, Gerber L, Reid J, et al. (2013). Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 86: 848-53
48. Cuzick J, Stone S, Fisher G, et al. (2015). Validation of an RNA cell cycle progression (CCP) score for predicting prostate cancer death in a conservatively managed needle biopsy cohort. Br. J. Cancer 113: 382-89
49. Crawford ED, Scholz MC, Kar AJ, et al. (2014). Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry. Curr. Med. Res. Opin. 6: 1025-31
50. Simon RM, Paik S, Hayes DF. (2009). Use of archived specimens in evaluation of prognostic and predictive biomarkers. J. Natl. Cancer Inst. 101: 1446-52
51. Bill-Axelson A, Holmberg L, Garmo H, et al. (2014). Radical prostatectomy or watchful waiting in early prostate cancer. N. Engl. J. Med. 370: 932-42
52. Karnes RJ, Bergstralh EJ, Davicioni E, et al. (2013). Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk population. J. Urol. 190: 2047-53
53. Cooperberg MR, Davicioni E, Crisan A, et al. (2015). Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur. Urol. 67: 326-33
54. Klein EA, Yousefi K, Haddad Z, et al. (2014). A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy. Eur. Urol. 67: 778-86
55. Bolla M, van Popel H, Tombal B, et al. (2012). Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-Term results of a randomised controlled trial (EORTC trial 2291). Lancet 830: 2018-27
56. AbrahamssonP-A, Anderson J, Boccon-Gibod L, et al. (2005). Risks and benefits of hormonalmanipulation as monotherapy or adjuvant treatment in localised prostate cancer. Eur. Urol. 48: 900-5
57. Stephenson AJ, Scardino PT, Eastham JA, et al. (2005). Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J. Clin. Oncol. 23: 7005-12
58. Ross AE, Feng FY, Ghadessi M, et al. (2014). A genomic classifier predictingmetastatic disease progression in men with biochemical recurrence after prostatectomy. Prostate Cancer Prostatic Dis. 17: 64-69
59. Den RB, Feng FY, Showalter TN, et al. (2014). Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy. Int. J. Radiat. Oncol. Bio. Phys. 89: 1038-46
60. Badani KK, Thompson DJ, Brown G, et al. (2015). Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery. BJU Int. 115: 419-29
61. Eggener SE, Scardino PT, Walsh PC, et al. (2011). Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J. Urol. 185: 869-75
62. Prensner JR, Rubin MA, Wei JT, et al. (2012). Beyond PSA: the next generation of prostate cancer biomarkers. Sci. Trans. Med. 4: 127rv3
63. Nguyen HG, Welty CJ, Cooperberg MR. (2015). Diagnostic associations of gene expression signatures in prostate cancer tissue. Curr. Opin. Urol. 1: 65-70
64. Sethi S, Kong D, Land S, et al. (2013). Comprehensive molecular oncogenomic profiling and miRNA analysis of prostate cancer. Am. J. Trans. Res. 5: 200-11
65. Tomlins SA, Mehra R, Rhodes DR, et al. (2007). Integrative molecular concept modeling of prostate cancer progression. Nat. Genet. 39: 41-51